Buckingham Strategic Partners Vertex Pharmaceuticals Inc Transaction History
Buckingham Strategic Partners
- $3.51 Billion
- Q2 2024
A detailed history of Buckingham Strategic Partners transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Buckingham Strategic Partners holds 722 shares of VRTX stock, worth $362,241. This represents 0.01% of its overall portfolio holdings.
Number of Shares
722
Previous 569
26.89%
Holding current value
$362,241
Previous $237,000
42.62%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding VRTX
# of Institutions
1,717Shares Held
226MCall Options Held
1.19MPut Options Held
1.56M-
Capital World Investors Los Angeles, CA26.7MShares$13.4 Billion2.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA23MShares$11.5 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$10.7 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.7MShares$5.88 Billion0.24% of portfolio
-
Capital Research Global Investors Los Angeles, CA8.54MShares$4.28 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $129B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...